Cell & Gene Therapy

Cell & Gene Supply Chain

From clinical to commercial, only Marken can seamlessly guide your cell and gene therapies through each stage of the biopharmaceutical logistics journey from vein-to-vein. To ensure cell and gene therapies are brought to market successfully, pharma and biotech companies must address logistical complexities within the clinical supply chain, which requires specialized solutions, industry-leading expertise and a rigorous control process coupled with advanced technology.

Supporting image

Marken’s unique cell and gene supply chain services feature industry-defining expertise consisting of specialized teams of biopharma industry and logistics specialists.

In addition, we provide direction on shifting regulatory and trade compliance guidelines and offer high-touch oversight from operations, project management, control tower, and quality teams. Explore more about our cell and gene services below.

Only Marken delivers the end-to-end capabilities and expert oversight needed to seamlessly guide your program through each stage of the pharmaceutical journey. Our experts and customer service specialists are available to discuss your Cell Therapy Supply Chain needs. Contact us on +1-800-627-5361 (US) or email info@marken.com

Related resources

Marken seamlessly orchestrates distribution of first commercial CAR-T therapy drug product from USA to Japan

28 April 2023

Marken successfully orchestrated the distribution of the first commercial CAR-T therapy drug product from the USA to a hospital in…

Marken’s 24/7 Cell & Gene Control Tower Provides Agile Solution for Critical Shipments

9 February 2023

Marken’s Cell and Gene Control Tower re-routed six critical shipments of CAR-T drug products from Amsterdam to the UK and…

Operational Excellence Overcomes Obstacles to Deliver Critical Autologous Cell Therapy

9 February 2023

Marken utilized operational excellence to deliver a critical autologous cell therapy. Although there were many challenges, Marken was able to…

Marken Successfully Safeguards the Viability of Pharmaceutical Samples Within 42 Hours

4 January 2023

The distribution of critical cell samples requires an agile strategy with contingency planning and regulatory expertise to ensure seamless delivery…

Happy Holidays from Marken

21 December 2022

At Marken, we are passionate about patients – always finding a way to deliver for our clients – on-time, within…

Marken Overcomes Multiple Obstacles To Successfully Deliver Critical Stem Cell Samples Across The Globe

9 December 2022

Stem cell samples require extremely tight 24-hour turnaround times in order to be modified and processed for critical cell therapy…

The Complex Demands of Personalized Medicine Supply Chains.

26 July 2021

Outsourcing-Pharma and Nina Vas, Marken’s Vice President, Clinical Distribution, Cell and Gene Therapy Supply Chain, discuss the specific requirements involved…

Evaluating a Clinical Supply Chain Partner to Meet Your Vaccine Trial Needs.

23 April 2021

It is essential for pharmaceutical companies to evaluate many factors when choosing a clinical supply chain partner. With today’s global…

Decentralized Trials Call for Supply Chain Flexibility: Marken

8 April 2021

Outsourcing-Pharma and Marken’s Vice President, Clinical Distribution, Cell and Gene Therapy Supply Chain, Nina Vas, and Senior Director of Global…

Marken Successfully Ensures On-Time Release Of CAR-T Cell Treatment In Spain

18 March 2021

Overcoming Brexit challenges to coordinate time-sensitive shipments About Marken Marken is a wholly owned subsidiary of UPS and is a…

Marken Makes It Happen COVID-19

13 October 2020

In these unprecedented times, we are coming together to achieve one shared goal: to beat COVID-19. The Marken team is…

Solving Complexities In the Era of the Personalized Medicine Supply Chain.

14 October 2019

Cell and gene therapies are fundamentally different than traditional medicines, from the patient and product journeys to the systems and…

View more

Delivering What Matters

Marken Logo

Understanding why we must adapt, continuously asking ourselves how we can change what matters is how we keep on delivering it.